Evaluation of an intratumorally administered slow release docetaxel formulation in combination with systemic anti-PD-1 treatment in a preclinical model. This is an ASCO Meeting Abstract from the 2018 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback